<DOC>
	<DOCNO>NCT02162667</DOCNO>
	<brief_summary>This study determine whether CT-P6 Herceptin equivalent patient early-stage breast cancer undergo neoadjuvant chemotherapy . Our hypothesis pathologic complete response rate equivalent patient treat neoadjuvant CT-P6 Herceptin . Patients receive 8 cycle neoadjuvant systemic therapy 10 cycle therapy adjuvant setting .</brief_summary>
	<brief_title>Efficacy Safety Evaluating Study CT-P6 Her2 Positive Early Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patient histologically confirm newly diagnose breast cancer Patient clinical stage I , II , IIIa operable breast cancer accord AJCC ( American Joint Committee Cancer ) Breast Cancer Staging 7th edition Patient HER2positive status confirm locally , define 3+ score IHC ( immunohistochemistry ) . Patient bilateral breast cancer Patient receive prior treatment breast cancer , include chemotherapy , biologic therapy , hormone therapy , immunotherapy , radiation surgery , include prior therapy anthracyclines .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>